Navigation Links
Inovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
Date:2/5/2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at RetailInvestorConferences.com.

DATE:    February 7, 2013
TIME:     3:00 PM EST
LINK:      www.retailinvestorconferences.com > red "register / watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015 Eli Lilly and Company (NYSE: ... quarter of 2015 on Thursday, April 23, 2015.  Lilly will ... investment community and media to further detail the company,s financial ... a.m. EDT. Investors, media, and the general public can access ... that will be posted on Lilly,s website at www.lilly.com ...
(Date:4/1/2015)... DALLAS , April 1, 2015 /PRNewswire/ ... Research Report on Global Azithromycin Industry and ... Drug Industry reports added to Pharmaceutical category ... analysis, the report introduces Azithromycin basic information, ... industry overview, policy analysis, and news analysis, ...
(Date:4/1/2015)... April 1, 2015  Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... offering of $60.0 million aggregate principal amount of ... in a private placement to qualified institutional buyers ... of 1933, as amended (the "Act"). Egalet also ...
Breaking Medicine Technology:Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7
... Stereotaxis, Inc. (NASDAQ:   STXS) today announced that ... Epoch platform, its comprehensive solution for the electrophysiology ... in procedures with a fully-remote, networked robotic and ... to the new generation Epoch platform from the ...
... -- Breadth of Pharmacokinetic Data Points to Tunable ... novel preclinical in vitro and in ... in an oral presentation at the American Society of ... presentation entitled "Discovery and Preclinical Characterization of a Novel ...
Cached Medicine Technology:Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 2Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 3Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers 4Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 2Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting 3
(Date:4/1/2015)... 01, 2015 Taking an important step ... League for Nursing Commission for Nursing Education Accreditation (NLN ... the first NLN CNEA Board of Commissioners. Working with ... the 15-member board will provide leadership and direction to ... accreditation decisions for nursing programs that seek accreditation from ...
(Date:4/1/2015)... Minn. (PRWEB) April 01, 2015 EAGAN, ... of Minnesota and its family of companies (Blue Cross) ... closed out the year with net income of $61.5 ... operational losses. The organization reported a net operating loss ... for a negative operating margin of one-tenth of one ...
(Date:4/1/2015)... San Diego, CA (PRWEB) April 01, 2015 ... promotion organization, is announcing two continuing medical education ... goal is to help practitioners become more confident ... to prevent disease. After completion of these CME ... , The CME courses available are ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Aging2.0 ... care, today announces the launch of the Aging2.0 ... senior care stakeholders and technology companies. The announcement was ... (NIC) Capital and Business Strategies Forum in San ... the new Alliance program is now open for additional ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 When annoying ... occur, waiting days or weeks for an appointment with ... same and next day appointments haven’t been possible within ... Forefront Dermatology’s offices have noticed demand for this level ... “We realize how important relief or answers to dermatological ...
Breaking Medicine News(10 mins):Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2
... new study shows that a large majority of patients who present ... IV) don,t require immediate surgery to remove the primary tumor in ... data today at the American Society of Clinical Oncology Annual Meeting. ... "For this population with metastatic ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... contradicted in research paper , , FRIDAY, May 29 (HealthDay ... follow a social order do not necessarily develop bigger ... Social Brain Hypothesis followed by many evolutionists. , ... Proceedings of the National Academy of Sciences ...
... the most common reason for hospitalisation in the over-65 ... 24 hours after admission in around 50% of these ... a more than 50% mortality and rehospitalisation rate at ... Cardiology Department of the University of Brescia, Italy, "it ...
... biomarkers have been recently described in Heart Failure (HF) ... settings of acute decompensation. Biomarkers are used to diagnose ... to individuals. , Speaking at a press conference at ... spokesperson for the European Society of Cardiology, presented these ...
... the symptoms of heart failure can be remotely assessed, ... of patients, according to Professor John Cleland from the ... 2009 that the management of heart failure is complex ... needs and condition.2 "Unfortunately," he added, "the resources required ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
The VersaFluor cuvette fluorometer is a fast and simple way to quantitate DNA, RNA, and proteins, to detect apoptosis, and to perform reporter enzyme assays with the high level of sensitivity and sel...
... DyNA Quant™ 200 is a ... excitation and 460 nm emission. The ... the detection of double-stranded DNA using ... assay, which minimizes interference from the ...
... fluorometer from Berthold Technologies, has been ... of measurement modes to support academic ... dual ratio measurements plus top and ... instrument for any researcher using fluorescence ...
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
Medicine Products: